-
1 Comment
Voxel S.A. is currently in a long term uptrend where the price is trading 8.3% above its 200 day moving average.
Voxel S.A.'s total revenue rose by 78.3% to $87M since the same quarter in the previous year.
Its net income has increased by 94.2% to $12M since the same quarter in the previous year.
Finally, its free cash flow fell by 34.1% to $3M since the same quarter in the previous year.
Based on the above factors, Voxel S.A. gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Diagnostics & Research |
| ISIN | PLVOXEL00014 |
| Exchange | WAR |
| CurrencyCode | PLN |
| Dividend Yield | 1.9% |
|---|---|
| Market Cap | 1B |
| PE Ratio | 16.84 |
| Target Price | 140.7 |
| Beta | 0.55 |
Voxel S.A. operates a network of diagnostic imaging laboratories in Poland. The company provides diagnostic imaging services, which include magnetic resonance imaging scans, computed tomography scans, and positron emission tomography; teleradiology services; ultrasound and X-ray examinations; and neuroradiosurgery services. It also involved in nuclear medicine research examinations business. In addition, the company operates neurological hospitals, laboratories for COVID-19 diagnostics, and information systems for hospitals; and offers clinical test services. Further, the company produces and sells radiopharmaceuticals products. Voxel S.A. was incorporated in 2005 and is based in Kraków, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VOX.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
